Continuing our latest cell therapy mini-series, this time around we focus on a novel and creative approach to CAR-T cell therapy, which is quite different from what we have described before with other companies in this niche.
One emerging trend is the development of bi- and even tri- specific approaches designed to target multiple aberrations in the cancer cells, but what’s the best way to achieve this? Suppose we ditch the core dogma and try another way of doing things?
The entirely new concept making the splash is also coming from an emerging young biotech company few readers will likely have heard of, yet what they are doing reminds me we can borrow from the past and paraphrase a watch ad from the 1980’s for elegant and simple timepieces – some day all CAR-Ts will be made this way.
The secret sauce this time around isn’t quartz, however, but something completely different…
To learn more from our oncology analysis and get a heads up on insights and commentary on an emerging novel and creative CAR T cell therapy approach, subscribers can log-in or you can click to gain access to BSB Premium Content.
The audience of Biotech Strategy Blog is a broad “church” (no pun intended) of professionals associated with cancer drug development.
Bridge of Sighs, Oxford
Some readers with a research focus noticed I was in Oxford recently then contacted me to ask what scientific papers I was reading and catching up on over the lazy summer months?
This got me thinking as I was vividly reminded of my days as a PhD student at King’s College London, where the department would regularly meet to discuss key papers and recent research.
If your work has a narrow focus, and that applies to industry too, it’s sometimes difficult to see what’s on the horizon or be stimulated by ideas outside your immediate field, yet cross-fertilisation is an important pillar of learning. That’s one of the advantages of BSB, we cover a wide range of topics, at varying levels of complexity.
Welcome to the BSB Journal Club!
In this inaugural post, I’ve selected several recently published cancer immunotherapy papers that caught my attention, also a couple of books for your summer reading.
In case you worry that the science is above your ‘pay grade,’ for each I’ve written a brief summary and highlighted what data means from a commercial/new product development persepctive. You are of course most welcome to agree/disagree and reach your own conclusions… I hope it will stimulate your thinking.
Science often moves forward and develops as people make connections from a broader perspective. I’m planning on running the “Journal Club” as a monthly ad hoc post to dovetail with the Reader Q&A Mailbag.
Subscribers can login or you can purchase access.